BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  CARBIOS announces the publication of its Interim report for the first half of 2025

  October 27, 2025

   · 

  2 min read
• Press Releases

  Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

  October 27, 2025

   · 

  16 min read
• Press Releases

  Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  October 27, 2025

   · 

  4 min read
• Press Releases

  SINOVAC Announces Appointment of Independent Auditor

  October 27, 2025

   · 

  4 min read
• Press Releases

  Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

  October 27, 2025

   · 

  7 min read
• Press Releases

  PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

  October 27, 2025

   · 

  9 min read
• Press Releases

  Parabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NCI-EORTC 2025

  October 27, 2025

   · 

  7 min read
• Press Releases

  BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  October 27, 2025

   · 

  5 min read
• Press Releases

  Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors

  October 27, 2025

   · 

  6 min read
• Press Releases

  Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference

  October 27, 2025

   · 

  7 min read